Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of human imatinib-sensitive and imatinib-resistant cells compared in the absence of imatinib
Both imatinib-sensitive and imatinib-resistant cells were compared in the absence of imatinib. The resistant cells in the presence of imatinib were compared to the sample in the absence of imatinib. The sample from the resistant cells in the presence of imatinib was labelled in duplicate to assess f...
ORGANISM(S): Homo sapiens 
2003-11-30 | E-MEXP-21 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human leukocytes from chronic myeloid leukemia patients exhibiting differing responses to imatinib
This is a class prediction experiment, where the class is the response status to imatinib (also called Gleevec), a drug used to treat patients with chronic myelogenous leukemia (CML). There are two data sets, a training set (from Leipzig, 8 Responders and 5 Non-Responders) and a validation set (fro...
ORGANISM(S): Homo sapiens 
2007-08-25 | E-GEOD-2535 | biostudies-arrayexpress
TranscriptomicsScleroderma and Gleevec treatment
Total RNA was extracted from skin biopsies before and after imatinib (Gleevec) treatment using Qiagen RNeasy fibrous tissue kit. RNA was amplified using the Ambion Amino Allyl MessageAmp II aRNA kit. Amplified skin RNA (labeled with Cy5) and amplified Stratagene Human Universal Reference RNA (labele...
ORGANISM(S): Homo sapiens 
2009-03-31 | E-GEOD-11130 | biostudies-arrayexpress
ProteomicsLIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance
Chronic myeloid leukemia (CML) resistance to BCR-ABL tyrosine kinase inhibitors (TKIs) can arise from ABL kinase domain mutations, BCR-ABL fusion gene amplification, or kinase-independent mechanisms. To investigate imatinib-resistance, we performed quantitative mass spectrometry comparing the proteo...
ORGANISM(S): Homo sapiens (Human) 
2026-01-22 | PXD066618 | Pride
Imatinib K562 Tki resistance Lin28a Phosphoproteomics 
TranscriptomicsTranscription profiling of human gastrointestinal stromal tumour is predictive of rapid response to imatinib mesylate
Gene expression profiling using oligonucleotide microarrays performed on tumor samples obtained before and after imatinib mesylate (IM) therapy. Rapid responding (to IM) samples were compared to non-responding/stable disease samples as measured by CT scan measurements to identify a gene signature t...
ORGANISM(S): Homo sapiens 
2009-12-02 | E-GEOD-15966 | biostudies-arrayexpress
TranscriptomicsImatinib treatment causes substantial transcriptional changes in adult Schistosoma mansoni in vitro exhibiting pleiotropic effects
Transcriptional profiling of Imatinib-treated paired adult S. mansoni vs. Non-treated (control) paired adult S. mansoni during 24 and 48 hours Two conditions (Imatinib-treated vs. Non-treated ) for each time of treatment (24 hours and 48 hours) with three biological samples of each conditions. For ...
ORGANISM(S): Schistosoma mansoni 
2014-06-20 | E-GEOD-53154 | biostudies-arrayexpress
TranscriptomicsTranscriptomic response of Saccharomyces cerevisiae to imatinib
Long-term effects of imatinib, a chemotherapy agent, on S. cerevisiae cells were investigated. Yeast cells were grown in the absence and presence of 400 mg/l imatinib in fully controlled bioreactors, in triplicates. Control cultures were described before, E-MTAB-6634.
ORGANISM(S): Saccharomyces cerevisiae 
2020-12-01 | E-MTAB-9042 | biostudies-arrayexpress
TranscriptomicsImatinib targeting of KIT-mutant oncoprotein in melanoma
Metastatic melanoma is an aggressive treatment-refractory malignancy. Recently, c-Kit mutations were discovered in certain mucosal melanomas. A clinical trial was initiated with the c-Kit inhibitor imatinib mesylate. The first treated patient experienced dramatic clinical improvement within days, f...
ORGANISM(S): Homo sapiens 
2008-12-23 | E-GEOD-8164 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of CD34 positive mononuclear cells from drug naive, chronic myeloid leukemia (CML) patients to determine an expression signature predictive of a major cytogenic response in CML patients treated with Imatinib.
Newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with a major cytogenetic response (MCyR) after 12 months of imatinib therapy have an excellent long-term outcome, while patients without MCyR have a high progression risk. Since patients with primary cytogenetic resistance may ben...
ORGANISM(S): Homo sapiens 
2009-12-31 | E-GEOD-14671 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human chromic myeloid leukemia (CML) patients treated second-line with imatinib after failure of an interferon-alpha based therapy to identify genes with predictive value for primary cytogenetic outcome to imatinib
Identification of genes in CML patients with predictive value for their primary cytogenetic outcome to imatinib. All samples analyzed were taken just before the start of imatinib treatment. Leukemic patients were treated second-line with imatinib after failure of an interferon-alpha based therapy (f...
ORGANISM(S): Homo sapiens 
2006-05-31 | E-MEXP-433 | biostudies-arrayexpress
Sort   by:  
 Page size